Among patients with stage IV adenocarcinomas, patients with EGFR-mutant tumors had a better survival [Hazard Ratio (HR): 0.43; 95% CI: 0.24–0.76]; again, receipt of erlotinib was not associated with survival. The gene discussed is EGFR; the disease is adenocarcinoma.